JP2014530242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530242A5 JP2014530242A5 JP2014535953A JP2014535953A JP2014530242A5 JP 2014530242 A5 JP2014530242 A5 JP 2014530242A5 JP 2014535953 A JP2014535953 A JP 2014535953A JP 2014535953 A JP2014535953 A JP 2014535953A JP 2014530242 A5 JP2014530242 A5 JP 2014530242A5
- Authority
- JP
- Japan
- Prior art keywords
- topical formulation
- formulation according
- ointment
- topical
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 12
- 239000002674 ointment Substances 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 6
- 235000011187 glycerol Nutrition 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 229960005150 glycerol Drugs 0.000 claims 4
- 229960004063 propylene glycol Drugs 0.000 claims 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 101001132652 Homo sapiens Retinoic acid receptor responder protein 2 Proteins 0.000 claims 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 3
- 102000048013 human RARRES2 Human genes 0.000 claims 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 101710170513 Retinoic acid receptor responder protein 2 Proteins 0.000 claims 2
- 102100033914 Retinoic acid receptor responder protein 2 Human genes 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546833P | 2011-10-13 | 2011-10-13 | |
| US61/546,833 | 2011-10-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530242A JP2014530242A (ja) | 2014-11-17 |
| JP2014530242A5 true JP2014530242A5 (enExample) | 2015-12-03 |
Family
ID=48082531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535953A Pending JP2014530242A (ja) | 2011-10-13 | 2012-10-12 | 皮膚疾病の処置用のケメリンｃ１５ペプチドの局所製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20140349943A1 (enExample) |
| EP (1) | EP2766032A4 (enExample) |
| JP (1) | JP2014530242A (enExample) |
| CN (1) | CN104159594A (enExample) |
| AU (1) | AU2012323952A1 (enExample) |
| CA (1) | CA2851643A1 (enExample) |
| HK (1) | HK1202064A1 (enExample) |
| WO (1) | WO2013056147A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN105120866B (zh) | 2013-01-23 | 2020-02-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US10233219B2 (en) * | 2013-04-12 | 2019-03-19 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
| CN103432073A (zh) * | 2013-09-11 | 2013-12-11 | 中国药科大学 | 一种肿瘤靶向纳米制剂及其制备方法 |
| WO2015153838A1 (en) * | 2014-04-02 | 2015-10-08 | Rogne Bioscience Inc. | Methods and compositions for treating inflammatory disorders |
| JP6719181B2 (ja) * | 2015-07-16 | 2020-07-08 | 花王株式会社 | 皮膚化粧料 |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| CN105277194B (zh) * | 2015-10-12 | 2019-01-08 | 南京信息工程大学 | 一种基于云平台的室内交互式引导实现方法 |
| WO2017127827A1 (en) | 2016-01-22 | 2017-07-27 | Tufts Medical Center | Compounds and methods for treating inflammation |
| HUE054241T2 (hu) * | 2016-03-28 | 2021-08-30 | Vidac Pharma Ltd | Stabil gyógyszerkészítmények topikális beadásra és alkalmazásuk |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| CN108192866B (zh) * | 2018-03-07 | 2021-05-11 | 郑州大学第一附属医院 | Sfn联合il-15和il-21制备记忆性t细胞的方法及应用 |
| WO2020028820A1 (en) * | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN109096368B (zh) * | 2018-09-30 | 2021-07-20 | 华南理工大学 | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 |
| WO2020178385A1 (en) * | 2019-03-06 | 2020-09-10 | Isdin, S.A. | Use of caprylic and capric triglycerides for the treatment of a disease or condition mediated by filaggrin or collagen deficiency |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| US11730705B2 (en) | 2019-05-02 | 2023-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Small molecule CMKLR1 antagonists in inflammatory disease |
| KR20230051117A (ko) * | 2020-01-10 | 2023-04-17 | 브리오리 바이오테크 인코포레이티드 | 로페콕시브를 함유하는 국소 조성물 및 이의 제조 및 사용 방법 |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN112190687B (zh) * | 2020-11-19 | 2022-06-10 | 温州医科大学附属第一医院 | 一种用于减少皮肤创伤瘢痕的药物及其应用 |
| CN112881668B (zh) * | 2021-01-18 | 2022-04-12 | 江苏省中医院 | 两种血清代谢物单独或联合用于制备诊断干燥综合征的试剂盒的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7419658B2 (en) * | 2001-07-09 | 2008-09-02 | Euroscreen S.A. | Isolated ligand of ChemerinR |
| US20060100145A1 (en) * | 2002-10-31 | 2006-05-11 | Ipf Pharmaceuticals Gmbh | Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases |
| GB0705488D0 (en) * | 2007-03-22 | 2007-05-02 | Isis Innovation | Treatment of inflammation and/or endotoxic shock |
| WO2009139817A2 (en) * | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2278993A4 (en) * | 2008-05-16 | 2012-09-12 | Corthera Inc | METHOD FOR PROMOTING HEALING |
| KR101559068B1 (ko) * | 2008-08-27 | 2015-10-20 | (주)아모레퍼시픽 | 키메린을 함유하는 지방세포 분화 억제 및 지방세포 내의 지질체 수준 감소용 조성물 |
| US20100092546A1 (en) * | 2008-10-10 | 2010-04-15 | Gurtner Geoffrey C | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds |
-
2012
- 2012-10-12 EP EP12839527.4A patent/EP2766032A4/en not_active Withdrawn
- 2012-10-12 JP JP2014535953A patent/JP2014530242A/ja active Pending
- 2012-10-12 HK HK15102607.4A patent/HK1202064A1/xx unknown
- 2012-10-12 WO PCT/US2012/060093 patent/WO2013056147A1/en not_active Ceased
- 2012-10-12 CA CA2851643A patent/CA2851643A1/en not_active Abandoned
- 2012-10-12 CN CN201280061652.5A patent/CN104159594A/zh active Pending
- 2012-10-12 US US14/352,296 patent/US20140349943A1/en not_active Abandoned
- 2012-10-12 AU AU2012323952A patent/AU2012323952A1/en not_active Abandoned
-
2015
- 2015-12-29 US US14/983,069 patent/US20160136231A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530242A5 (enExample) | ||
| AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
| WO2009053741A3 (en) | Novel formulation | |
| JP2015522049A5 (enExample) | ||
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| JP2013515002A5 (enExample) | ||
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| JP2012531448A5 (enExample) | ||
| JP2016512246A5 (enExample) | ||
| JP2002526407A5 (enExample) | ||
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| JP2019524774A5 (enExample) | ||
| JP2012508256A5 (enExample) | ||
| JP2013520448A5 (enExample) | ||
| JP2010510194A5 (enExample) | ||
| RU2012149868A (ru) | Полисахарид семян для применения в лечении воспалительных заболеваний | |
| JP2012525358A5 (enExample) | ||
| JP2016538288A5 (enExample) | ||
| NZ719321A (en) | Storage stable lyophilized tripeptide formulations | |
| EP3294267A1 (en) | Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity | |
| JP2015513554A5 (enExample) | ||
| RU2019102890A (ru) | Фармацевтические композиции, содержащие флурбипрофен | |
| RU2013142445A (ru) | Фармацевтический препарат для местного применения, содержащий в-220 | |
| CO6241114A2 (es) | Composicion farmaceutica que comprende la combinacion del agente antimicrobiano ciprofloxacino y el agente antioxidante acido ascorbico para el tratamiento de infecciones urinarias |